Actinium Pharmaceuticals, Inc. (ATNM) AI Stock Analysis

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm advancing therapies primarily focused on bone marrow transplant (BMT) and adoptive cell therapies. Its core pipeline asset is I-131 apamistamab (Iomab-B), which is in pivotal Phase III trials for BMT conditioning in elderly patients with relapsed or refractory acute myeloid leukemia. It also conducts a Phase I study with Memorial Sloan Kettering Cancer Center for a CD19-targeted CAR T-cell therapy. The company leverages Actinium-225, Iodine-131, and Lutetium-177 across programs targeting CD45, CD33, CD38, CD47, HER2, and HER3. Collaborations include Astellas Pharma, Inc., EpicentRx, Inc., and AVEO Oncology.

Annual revenue fluctuated from $622,000 in FY2020 to $1.1M in FY2021 and $1.0M in FY2022, before falling to $81,000 in FY2023 and slightly rebounding to $90,000 in FY2025. Net income was -$22.2M in FY2020, -$24.8M in FY2021, -$33.0M in FY2022, -$48.8M in FY2023, and -$33.9M in FY2025. From FY2020 to FY2025, revenue contracted at a compound annual growth rate of -38.3%. For the trailing twelve months ended June 30, 2026, revenue reached $35.1M with an operating margin of 78.8% and EPS of $0.35, though quarterly revenue growth declined 100.0% year-over-year.

As of June 30, 2026, Actinium held $36.5M in cash and short-term investments against total debt of $1.3M, resulting in net cash of $35.1M. Shareholders' equity stood at $30.3M and total assets were $40.2M, with a current ratio of 4.08 and a debt-to-equity ratio of 0.04. During FY2025, operating cash flow was -$24.6M and free cash flow was -$24.7M. Capital allocation in FY2025 included $104,000 for capital expenditures and $207,000 for share buybacks, while the share count rose 45.8% over five years.

ATNM has a market capitalization of $35.5M and an enterprise value of $2.0M. The stock trades at a trailing P/E of 3.2x and a forward P/E of 8.5x, well below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its price-to-sales ratio of 1.0x and EV/EBITDA of 0.2x also compare to peer medians of 4.1x and 12.0x. Over the past year, the stock fell 22.6%, trailing the S&P 500 (SPY) gain of 16.8%. Over five years, the stock dropped 85.9% compared to an 83.0% increase for SPY.

Actinium currently carries 2 Strong Buy, 2 Buy, and 1 Hold ratings from Wall Street analysts. The mean price target is $3.60, representing an upside of 218.6% from the last close of $1.13. For the fiscal year ending December 31, 2026, analysts estimate revenue of $17.5M and EPS of $0.14. For the next fiscal year, two analysts project revenue of $0 and an EPS of -$0.53. Actinium has beaten EPS estimates in 3 of the last 4 quarters, with its next earnings announcement scheduled for November 13, 2026.

This page is an AI-written research summary of Actinium Pharmaceuticals, Inc. (ATNM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ATNM income statement, ATNM balance sheet, ATNM key metrics, ATNM analyst forecast, ATNM chart. See the ATNM stock overview for the latest quote and news.